Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release

• Published in: Peptides (New York, N.Y. : 1980) Vol. 8; no. 2; p. 199
• Main Authors: Simard, J, Lefèvre, G, Labrie, F
• Format: Journal Article
• Language: English
• Published: United States 01-03-1987
• Subjects: Animals; Cyclic AMP - metabolism; Female; Growth Hormone - metabolism; Growth Hormone-Releasing Hormone - antagonists & inhibitors; Growth Hormone-Releasing Hormone - pharmacology; In Vitro Techniques; Kinetics; Pertussis Toxin; Pituitary Gland, Anterior - drug effects; Pituitary Gland, Anterior - metabolism; Rats; Rats, Inbred Strains; Somatostatin - pharmacology; Virulence Factors, Bordetella - pharmacology
• ISSN: 0196-9781
• DOI: 10.1016/0196-9781(87)90090-8

We have investigated the effect of prior exposure to somatostatin (SRIF) alone or in combination with growth hormone-releasing factor (GRF) on the subsequent cyclic AMP and GH responses to GRF in rat anterior pituitary cells in primary culture. The maximal 4.5-fold stimulation of GH release induced by a 3-hr incubation with GRF is reduced by 60% following a prior 3-hr exposure to 30 nM GRF. A 3-hr preincubation with GRF in the presence of 30 nM SRIF doubles spontaneous GH release while the maximal amount of GH released during a subsequent 3-hr exposure to GRF is similar to that measured in cells pretreated with control medium, thus completely preventing the loss of GH responsiveness induced by prior exposure to GRF. The prevention by SRIF of the desensitizing action of GRF on GH release is not observed on the cyclic AMP response which remains almost completely inhibited in GRF-pretreated cells. Similar protective effects are obtained when SRIF is incubated with prostaglandin E2 (PGE2), thus completely preventing the desensitizing action of PGE2 on GH release. Prior treatment with pertussis toxin completely prevents the protective action of SRIF on GH responsiveness. Pretreatment with GRF + SRIF increases by 85 and 60% the maximal amount of GH release induced by cholera toxin and 8-bromoadenosine 3',5'-monophosphate, respectively. The post-SRIF rebound effect on GH release occurs mainly during the first 30 min following withdrawal of the tetradecapeptide. The present data demonstrate that simultaneous preincubation with SRIF and GRF prevents the marked inhibition of GH release during subsequent exposure to GRF.